Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)Michele Marchioni, Maria Carmen Mir, Thomas Amiel et al.|European Urology Oncology|2020Cited by 34
MP14-07 PERFORMANCE OF A NEW RISK ASSESSMENT TOOL FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA UNDERGOING CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: REMARCC SCOREM Mir, Michele Marchioni, Riccardo Campi et al.|The Journal of Urology|2020Cited by 0